Universita' Degli Studi Di Perugia

7 trials 3 recruiting Academic / non-commercial Merged from 5 name variants

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

3 Completed trials

4 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (FiH)

Phase III: 1 Phase II: 3 Phase IV: 2 Phase I (FiH): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hairy cell leukaemia 1

Top IMPs

PEMBROLIZUMAB 2 VEMURAFENIB 2 AMOXICILLIN TRIHYDRATE 1 BRENTUXIMAB VEDOTIN 1 CLADRIBINE 1 COBIMETINIB 1 INDOCYANINE GREEN 1 NIVOLUMAB 1 OBINUTUZUMAB 1 RITUXIMAB 1 RUXOLITINIB 1

All trials

7 total

HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY) Pending

2024-519107-10-00 Phase IV 1 country
Monocentric, open-label, single-arm, phase I/II clinical trial to evaluate the use of the ONCOGREEN galenic formulation consisting of indocy… Recruiting

2025-521273-14-00 Phase I (FiH) 1 country INDOCYANINE GREEN
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 Phase III 3 countries NIVOLUMAB; PEMBROLIZUMAB
VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting

2024-520119-41-00 Phase II 1 country CLADRIBINE; RITUXIMAB; VEMURAFENIB
STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE… Ended

2024-520121-36-00 Phase II 1 country COBIMETINIB; OBINUTUZUMAB; VEMURAFENIB
The effect of different antibiotic protocols for dental implant surgery on peri-implant tissue health and on oral microbiome and resistome Ended

2023-510391-31-00 Phase IV 1 country AMOXICILLIN TRIHYDRATE
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab… Ended

2024-520123-83-01 Phase II 1 country BRENTUXIMAB VEDOTIN; PEMBROLIZUMAB; RUXOLITINIB

Showing 1–7 of 7 trials

← All sponsors A–Z